KLK6 and pancreatic ductal adenocarcinoma: Recently, we showed that APPI‐4M could be leveraged as tool to investigate the role of KLK6 in the TME of pancreatic ductal adenocarcinoma [63] In that model, the selective and robust inhibition of KLK6 by APPI‐4M also reduced KLK6 mRNA expression, cell metabolic activity, and KLK6 secretion, but, in turn, increased the secretion of other serine and aspartic lysosomal proteases.